The global DNA and gene cloning services market size is anticipated to reach USD 6.82 billion by 2030, growing at a CAGR of 15.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising acceptance of gene therapy and advancements in DNA and gene cloning technology are factors expected to propel market growth. Moreover, the increasing demand for personalized medicine further drives market growth.
Gene cloning facilitates the development of personalized treatments by identifying specific genetic mutations responsible for diseases. By targeting these mutations through gene therapy, personalized medicine offers more effective and targeted treatment options. Integrating gene cloning technologies into personalized medicine is expected to drive further growth in the DNA and gene cloning services market. As research continues to uncover new genetic targets for therapy and diagnostics, the demand for advanced DNA cloning services will likely increase to support personalized treatment approaches.
The COVID-19 pandemic has significantly impacted the DNA and gene cloning services market. The increased demand for synthetic biology products, driven by the urgent need for COVID-19 vaccines and treatments, has accelerated research and development (R&D) in cloning technology. Moreover, despite the challenges posed by the pandemic, the DNA and gene cloning services market is expected to continue growing steadily due to the increasing adoption of novel technologies, the rising demand for gene therapies, and ongoing advancements in genetic engineering.
However, one of the primary concerns of the misuse of gene cloning and synthesis technology is the creation of harmful pathogens through synthetic biology techniques to develop bioweapons. Improper handling or disposal of synthetic DNA could lead to environmental contamination. Engineered organisms released into the environment could have ecological consequences.
Request a free sample copy or view report summary: DNA and Gene Cloning Services Market Report
Gene synthesis dominated the service segment in 2023 as they play a crucial role in synthetic biology by enabling the creation of custom DNA sequences without the need for a template.
In 2023, DNA sequencing dominated the application segment in terms of revenue and is expected to grow at the highest CAGR from 2024 to 2030. Furthermore, mutagenesis segment is expected to grow at a significant CAGR over the forecast period.
Academic & research institutes dominated the end use market with the largest share of 38.41% in 2023, driven by their significant contribution in the R&D to bring novel gene therapy treatments and engineered biotechnological products to market.
The CMOs & CROs segment is anticipated to grow at the fastest CAGR from 2024 to 2030 due to their increasing adoption and investment in advanced research and manufacturing technologies.
North America region dominated the DNA and gene cloning services market with a share of 40.98% in 2023 owing to factors such as increasing investments in R&D activities, rising demand for personalized medicine, and advanced biotechnology research infrastructure.
Grand View Research has segmented the global DNA and gene cloning services market based on the service, application, end use, and region:
Service Outlook (Revenue, USD Million, 2018 - 2030)
Gene Synthesis
Custom Cloning
Sub-cloning
Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
DNA Sequencing
Mutagenesis
Genotyping
Others
End use Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
CMOs & CROs
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the DNA and Gene Cloning Services Market
Bio-Techne
Charles River Laboratories
Eurofins Scientific
GenScript
Danaher Corporation
Syngene International Limited
Twist Bioscience
Thermo Fisher Scientific Inc.
Merck KGaA
Curia Global, Inc.
"The quality of research they have done for us has been excellent..."